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Abstract
Background: Patient-activated event recorders (ER) can facilitate diagnosis in unclear palpi-
tations, however impact of ER screening on further treatment in clinical routine is unknown. 
We investigated the feasibility and clinical value of a network-based telemetric monitoring 
using a patient activated ER.
Methods: The network consisted of 12 general practitioners (GP) and a department of car-
diology (DC). GP-patients sent electrocardiograms (ECGs) twice daily and in case of palpita-
tions. ECGs were transferred by email to GP and DC and analyzed independently by both. The 
therapeutic strategy was discussed between GP and DC. The monitoring period ended after  
4 weeks or in case of detected arrhythmia.
Results: A group of 184 consecutive patients were retrospectively analyzed. Mean age was  
57.5 ± 14.4 years (range 17–82), 104 (56.5%) were female. Significant arrhythmia occurred in 
71 (38.5%) patients: Recurrence of known paroxysmal atrial fibrillation (AF; n = 27, 14.7%), 
de novo AF (n = 19, 10.3%), premature complexes/bigeminus (n = 13, 7.1%), sinus tachycar-
dia (n = 7, 3.8%), atrioventricular nodal reentrant tachycardia (n = 3, 1.6%), and ventricular 
tachycardia (n = 2, 1.1%). A therapeutic consequence resulted in 63 (88.7%) patients with de-
tected arrhythmia: new oral anticoagulation (n = 29, 40.8%), new antiarrhythmic medication 
(n = 27, 38.0%), behavioral intervention (n = 19, 26.8%), electrophysiology-study/catheter 
ablation (n = 4, 5.6%), cardioversion (n = 2, 2.8%), implantable cardioverter-defibrillator-
-implantation (n = 1, 1.4%), and left atrial appendage occluder (n = 1, 1.4%).
Conclusions: The investigated cross-sector telemetric network is a feasible approach to detect 
arrhythmia in patients with palpitations and may have high impact on further treatment, no-
tably in those at risk for stroke due to AF. (Cardiol J 2016; 23, 4: 422–428)
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Introduction
Palpitations suggestive of cardiac arrhythmia 
are a common symptom in outpatients seeking 
medical attendance [1]. Less than a half of those pa-
tients suffer from cardiac arrhythmia [2]. A 12-lead 
 electrocardiogram (ECG) during symptoms as the 
gold standard of defining arrhythmia in symptomat-
ic patients can be obtained only in about 30% [3]. 
Due to the transient nature of most arrhyth-
mias, detection can be challenging. From 24 h to 
48 h Holter ECG is still the standard of care for these 
patients, nevertheless it has a low diagnostic yield [4]. 
Implantable loop recorders are the gold standard 
of prolonged ambulant rhythm monitoring [5]. 
However, their use is restricted due to high costs, 
invasiveness with up to 1% of pocket infections 
and cosmetic aspects [6]. Patient-activated event 
recorders (ER) have shown to be useful in this 
clinical setting. A higher diagnostic value compared 
to standard care with a higher number of relevant 
diagnoses has been reported in several studies as 
reviewed by Hoefman et al. [7]. Most of these tri-
als have been conducted in tertiary care settings. 
In studies with primary care patients, ECGs were 
analyzed by external cardiologists. This appears 
to be necessary due to possible lack of expertise 
in detecting arrhythmias, such as atrial fibrillation 
(AF) by general practitioners (GP) [8]. However, 
external review of ECGs does not reflect the usual 
clinical routine. No data about the impact of ER-
screening on further therapy in clinical practice 
exist. Hence, there is insufficient information 
about the therapeutic impact of these devices in 
a real-world setting in primary care. The aim of 
this study was to assess the diagnostic value and 
therapeutic impact of ERs in a newly established 
cross-sector telemedical network.
Methods
The study complies with the Declaration of 
Helsinki and was approved by the Ethics Commit-
tee of the University Witten/Herdecke.
Description of the network
Twelve GPs were invited to take part in the 
network and were provided with 2 ERs each. The 
GPs were instructed to apply ER monitoring in 
patients in sinus rhythm presenting with infre-
quent palpitations. The inclusion criteria were: 
palpitation (defined as the perception of a fast and/ 
/or irregular heartbeat) appearing at least once in 
4 weeks and non-diagnostic resting ECG and 24 h 
Holter monitoring. The exclusion criteria were: 
less frequent symptoms, presence of implanted 
rhythm devices and patient’s disability to record 
and transmit ECGs due to cognitive or physical 
impairment. The GP obtained informed consent 
and explained the use of the device. When a patient 
was selected for monitoring the GP sent a fax to the 
department of cardiology (DC) with the patient’s 
data, clinical characteristics, and the serial number 
of the device. After 1 successful test transmission, 
patients were instructed to record and transfer 
ECGs twice daily and in case of palpitations. These 
daily routine ECG recordings intended to screen 
for asymptomatic AF episodes. In case of missing 
ECG transferals, the patients were contacted by 
phone by the GP staff. Technical issues and com-
prehension problems were solved by phone or in 
an additional practice appointment. In the DC, 
5 experienced cardiologists analyzed the incom-
ing ECGs daily. In case of detected arrhythmia, 
GP and DC discussed the further diagnostic and 
therapeutic approach by phone. The monitoring 
period ended after 4 weeks or in case of detected 
arrhythmia. A 4-week monitoring period was 
chosen for an optimum sensitivity of arrhythmia 
detection in patients with infrequent symptoms. 
Longer telemetry periods did not show additional 
benefit [3, 9].
Technical characteristics
In all cases, a Tele-EKG-Card 100IRTM (Vita-
phone, Mannheim, Germany) was used (Fig. 1). 
This card consists of a memory unit that can store 
up to three 30 s single lead ECGs. Patients have to 
wear the device around the neck. In case of palpi-
tations, the ECG card is pressed to the precordial 
region and activated by a button. Four fixed metal 
electrodes on the back of the device conduct signal 
transfer. Due to absent adhesive electrodes, there 
is no permanent electrical contact, i.e. there is no 
looping memory function. Guided by voice com-
mands the patient sends the recorded acoustically 
encoded episodes to the Vitaphone server via 
a toll free number. Data is transformed to PDF- 
-ECG files and transmitted to the clients via email. 
ECGs were assigned to an individual patient by the 
serial number of the device. Further information 
regarding symptoms was not specified in order to 
simplify the screening.
Follow-up
Monitoring results and the subsequent treat-
ment were documented by the GP until the end 
of follow-up. Six months after the end of the last 
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patient’s monitoring period the GP’s patient re-
cords were reviewed for diagnostic results and the 
following therapeutic interventions based on ER 
monitoring: new or altered medical treatment (an-
tiarrhythmics and anticoagulation), cardioversion, 
electrophysiology-study/catheter ablation, device 
therapy, left atrial appendage (LAA) occlusion, and 
behavioral intervention.
Results
Diagnoses
From October 2012 to July 2014, 184 patients 
with mean age 57.5 ± 14.4 years (range 17–82), 
were monitored, 104 (56.5%) were female (for 
general characteristics see Table 1). There were 
no dropouts due to technical or compliance prob-
lems. The device has no quality feedback function 
to reassure patients about the success of ECG re-
cordings. Nevertheless, insufficient signal quality 
due to lack of electrical contact or motion artifacts 
was seen only in single ECGs. One hundred and 
thirteen (61.4%) patients had no arrhythmic event. 
The majority of arrhythmic patients had recur-
rence of known paroxysmal AF (PAF) (n = 27, 
14.7%); 17 (9.2%) with CHA2DS2VASc score > 1; 
followed by de novo AF (n = 19, 10.3%); 12 (6.5%) 
with CHA2DS2VASc score > 1. Atrioventricular 
nodal reentrant tachycardia (AVNRT) was found 
in 3 (1.6%) patients. Sustained and non-sustained 
ventricular tachycardia was detected in 1 patient, 
respectively. Less relevant arrhythmia, such as 
sinus tachycardia and premature complexes, was 
found in 20 (10.9%) patients. None of the arrhyth-
mic patients reported symptoms of circulatory 
compromise. Findings on ER monitoring are sum-
marized in Table 2. Figure 2 shows examples of 
pathologic single lead-ECG.
Therapeutic consequences
Oral anticoagulation (OAC) was started in 
14 out of 19 (73.7%) patients with de novo AF and 
in 15 out of 27 (55.5%) patients with recurrence of 
known PAF. This corresponds to new OAC in 15.8% 
based on all patients studied. The remaining were 
already anticoagulated, had CHA2DS2VASc scores 
£ 1 or refused OAC. In 7 of newly anticoagulated 
patients, direct OACs were given instead of vitamin 
K antagonists (VKA) after agreement between DC 
and GP. Of 46 AF patients 2 (1 with known PAF, 
1 with new AF) were found to have persistent AF; 
cardioversion was successfully performed after 
transesophageal echocardiography. In 1 patient 
with recurrence of PAF and history of gastroin-
testinal bleeding under VKA treatment as a result 
of esophagus varices due to liver cirrhosis and no 
OAC at the time of monitoring LAA occlusion was 
performed. In two highly symptomatic patients 
(1 with known PAF, 1 with new AF), sinus rhythm 
could be restored by pulmonary vein isolation. 
Three patients had AVNRT. Two of them had 
electrophysiology study and catheter ablation, 
1 was treated medically due to young age and 
less severe symptoms. In 1 patient, detection 
Figure 1. Tele-EKG-Card 100IRTM (Vitaphone, Mannheim, Germany).
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of a sustained ventricular tachycardia resulted 
in further cardiologic evaluation. Implantation of 
an implantable cardioverter-defibrillator (ICD) 
was performed after dilative cardiomyopathy was 
diagnosed. In a 25-year-old female patient, recur-
rent non-sustained ventricular tachycardia was 
found. Structural heart disease was excluded, beta-
blocker medication was started resulting in relief of 
symptoms. Antiarrhythmic medication was started 
in a total of 27 (38.0%) patients. In 5 of 20 patients 
with less relevant arrhythmia (sinus tachycardia, 
bigeminus, premature complexes), antiarrhythmic 
therapy with beta-blockers was initiated, 19 had 
short behavioral intervention which encompassed 
a 20-min educational conversation about the benign 
nature of the detected arrhythmia and possible 
coping strategies.
In ER negative patients and in the group with 
less relevant arrhythmia, there were no cardiologic 
referrals or hospital admissions, and neither in- nor 
outpatient emergency treatments on follow-up. 
Table 3 summarizes therapeutic consequences in 
patients with detected arrhythmia.
Discussion
Palpitations are a common symptom in gen-
eral practice. GP can rarely establish a diagnosis 
in the case of infrequent palpitations due to the 
low sensitivity of 24 h Holter monitoring. This 
diagnostic dilemma leads to a significant number 
of hospital admissions, emergency treatments, and 
cardiologic referrals.
The present study shows that patient-trig-
gered event recorders can be effectively integrated 
in the routine workup of patients with unclear 
palpitations in a cross-sector telemedical network.
The approach was suitable for the detection of 
AF, which is the most common clinically relevant 
arrhythmia in the general population. The clini-
cal impact of AF is high: AF leads to a threefold 
increased risk of developing heart failure; risk of 
stroke is 5-fold increased, and doubled mortal-
ity rates have been described [10]. Stroke due 
to AF leads to death or severe disability in over 
70% cases [11]. Recent research on cryptogenic 
stroke has highlighted silent AF as a major cause 
of stroke [12].
Our study indicates that despite the generally 
benign character and excellent short-term prog-
nosis [2] of palpitations, screening for AF exceed-
ing standard workup is warranted, particularly in 
patients with CHA2DS2VASc-score > 1 in order to 
rule out AF as a cause of palpitations [13].
Although OACs can lower the risk of stroke 
due to AF by over 60% and mortality rates by 25% 
[14], they can only be used in documented AF. 
Table 2. Findings on event recorder monitoring.
N %
No arrhythmia (sinus rhythm) 113 61.4
Relevant arrhythmia 71 38.6
Recurrence of AF: 27 14.7
CHA2DS2VASc > 1 17 9.2
Without pre-existing OAC 16 8.7
CHA2DS2VASc > 1  
without pre-existing OAC
11 6.0
New AF: 19 10.3
CHA2DS2VASc > 1 12 6.5
Premature complexes/bigeminus 13 7.1
Sinus tachycardia 7 3.8
AVNRT 3 1.6
Sustained VT 1 0.5
Non-sustained VT 1 0.5
AF — atrial fibrillation; AVNRT — atrioventricular nodal reentrant 
tachycardia; OAC — oral anticoagulation; VT — ventricular tachy-
cardia
Table 1. Baseline characteristics (total patients: 
n = 184).
Mean or N Range or %
Age [years] 57.5 ± 14.4 17–82
CHA2DS2VASc score 1.9 ± 1.4 0–6
Female 104 56.5
Age groups [years]:
< 50 55 29.9
50–64 62 33.7
65–75 52 28.3
> 75 15 8.2
Congestive heart failure 6 3.3
Hypertension 103 56.0
Diabetes mellitus 16 8.7
Previous stroke 10 5.4
Coronary artery disease 21 11.4
Known paroxysmal AF: 52 28.3
CHA2DS2VASc > 1 35 19.0
Without pre-existing 
OAC
26 14.1
CHA2DS2VASc > 1 
without pre-existing 
OAC
18 9.7
AF — atrial fibrillation; OAC — oral anticoagulation
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Table 3. Therapeutic consequences in patients 
with detected arrhythmia (total: n = 71*).
N %*
Any therapeutic consequence 63 88.7
New oral anticoagulation: 29 40.8
Known paroxysmal AF 15 21.1
Known paroxysmal AF  
CHA2DS2VASc > 1
11 15.5
De novo AF 14 19.7
De novo AF CHA2DS2VASc > 1 12 16.9
VKA 22 31.0
DOAC 7 9.9
Antiarrhythmic medication 27 38.0
Behavioral intervention 19 26.8
Electrophysiology-study/ 
/catheter ablation
4 5.6
Cardioversion 2 2.8
LAA-occluder 1 1.4
ICD implantation 1 1.4
*Multiple therapeutic consequences in a number of patients generate 
a sum of percentages > 100%. AF — atrial fibrillation; VKA — 
vitamin K antagonist; DOAC — direct oral anticoagulant; LAA — 
left atrial appendage; ICD — implantable cardioverter-defibrillator
Figure 2. Examples of pathologic findings on transmitted single lead — electrocardiograms (ECGs). Only the first 
10 s of the 30 s — ECG strip are displayed; A. Atrial fibrillation; B. Atrioventricular nodal reentrant tachycardia; 
C. Ventricular tachycardia.
Being often asymptomatic and transient, AF mostly 
evades detection by 24 h Holter ECG. Studies 
showing that prolonged screening for AF is effec-
tive [15] had little influence on clinical routine. 
This may be due to insufficient awareness of the 
problem in daily clinical practice and the lack of 
a practicable diagnostic approach in primary care. 
Integrated in a cross-sector telemedical network, 
the patient-activated ER is applicable for routine 
use in outpatients with suspected PAF. Combining 
symptom-triggered and routine ECG-transmission 
for palpitations appears to be effective in the detec-
tion of AF and it is well accepted by the patients.
The clinical impact of the established diagno-
ses was high, notably case discussion between GP 
and DC led to 100% (12/12) anticoagulation rate in 
de novo AF patients with a CHA2DS2VASc score > 1 
on follow-up.
There is evidence that auto-triggered detec-
tion of arrhythmia may be more effective in diag-
nosing relevant arrhythmia, particularly AF, than 
the patient-triggered mode alone [16]. However, 
adhesive electrodes are necessary, which can be 
inconvenient when used over a long period of 
time. We used a device without a looping memory 
to improve patient compliance and convenience 
and combined symptom-triggered monitoring 
with routine ECG transferal twice daily to screen 
for asymptomatic AF. This approach has been 
successfully employed in previous trials on post-
therapeutic recurrence of AF: the device was 
equally effective as 7-day Holter monitoring [17] 
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and is supported by the European Heart Rhythm 
Association guideline on indications for diagnostic 
loop recorders [5]. In a recently published STUDY- 
-AF trial [18], an external continuous loop recorder 
with auto-detection of AF was used in asympto-
matic patients with the following AF risk factors: 
coronary heart disease, heart failure, hypertension, 
diabetes mellitus, and sleep apnea to screen for 
silent AF. We could show a higher detection rate 
(5.3% vs. 10.3%) of de novo AF. This indicates that 
the presence of palpitations may correlate with 
a higher rate of detected AF in patients at risk for 
AF and its sequelae. Another study [19] inves-
tigated patients with palpitations using a device 
similar to the Tele-EKG-Card 100IRTM and found 
only 2.6% of not further specified atrial tachycardia. 
Monitoring was limited to 15 days. This supports 
the finding that a monitoring period of 4 weeks is 
preferable [3].
Event recorder screening was not limited to 
patients without previously diagnosed arrhyth-
mia. Thus, patients with known PAF were also 
screened. Interestingly, only a half of 52 patients 
with known PAF and palpitations showed recur-
rence of AF in the monitoring period. We conclude 
that palpitations in PAF patients should not gen-
erally be attributed to PAF. One of those patients 
had sustained ventricular tachycardia requiring 
ICD implantation; most were in sinus rhythm. 
Furthermore, screening patients with known PAF 
can also be of relevance regarding anticoagulation 
management. Many AF patients are not treated 
with OAC despite a CHA2DS2VASc score > 1 
and missing contraindications [20]. In our study, 
18 (51.4%) patients with known PAF and a CHA2- 
DS2VASc score > 1 (n = 35, 67.3%) did not receive 
OAC. Eleven (61.1%) of them had AF on moni-
toring. Detection of recurrent PAF led to 100% 
anticoagulation rate in ER positive patients with 
a CHA2DS2VASc score > 1 and no OAC prior to 
ER-screening. Thus, discussion between GP and 
DC may be beneficial for better implementation 
of guideline conform therapy. Patients without 
arrhythmia on ER-screening were not subject to 
discussion between GP and DC; accordingly, also 
patients with known PAF that did not show recur-
rence of PAF on screening. Nine of these patients 
had a CHA2DS2VASc score > 1. Case discussion 
might have been beneficial also in these patients 
because ER screening cannot exclude recurrence 
of AF in 100%.
The network approach provides an efficient 
communication between GP and DC and fast 
clinical decision-making. This link between GP 
and DC has special significance for AF-patients. 
Decisions about anticoagulation have to take into 
account compliance issues, risk of falls, and bleed-
ing complications. GPs have more insight in daily 
life aspects and in the morbidity of their patients. 
On the other hand, cardiologic expertise is needed 
to decide what strategy (rate vs. rhythm control/ 
/anticoagulation vs. LAA-occluder) is most suit-
able. The network is a good platform for structured 
communication about rhythm management and 
allows for an individualized approach, minimizing 
loss of information. This is reflected by a high over 
all number of initiated treatments.
Despite absence of severe arrhythmia, life can 
be impaired due to the recurrence of symptoms 
and insecurity in patients with unclear palpitations 
leading to hospitalizations or intensified diagnostic 
efforts. We could show that ruling out severe ar-
rhythmia in the monitoring period may be helpful in 
limiting further diagnostic efforts: during 6-month 
follow-up, there were no planned hospital admis-
sions, cardiologic referrals, or emergency treat-
ments of those patients.
Although failure of device activation or ECG- 
-transmission by the patient can occur [21], this was 
an irrelevant obstacle in the present trial, mainly 
because patients were contacted by the GP staff 
in the case of missing routine ECG transmission.
The present study shows that network-based 
ER-monitoring can be a useful part in a graduated 
diagnostic approach to palpitations closing the gap be-
tween standard 24 h Holter monitoring and more cost 
intensive and invasive implantable loop recorders.
Limitations of the study
One major limitation of this study is the miss-
ing control group. Secondly, excluded patients 
were not registered and, therefore, could not be 
analyzed. We encourage controlled prospective-
randomized trials in order to clarify the clinical 
significance of our results. To simplify the ap-
proach, symptoms during monitoring were not 
documented. Therefore, arrhythmic episodes could 
not be attributed as symptomatic or asymptomatic. 
However, the intention of the network to exclude 
prognostically relevant arrhythmia is unaffected by 
this issue. Screening for AF with ECG monitoring 
twice daily cannot exclude AF by 100%; the screen-
ing method has a sensitivity of about 70% [5]. 
Implantable loop recorders are the gold standard 
regarding AF detection. However, implantable loop 
recorders implantation appears to be no reasonable 
first-line approach for screening in the group of 
patients studied.
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There was no general screening for structural 
heart disease prior to inclusion. In order to keep 
our approach simple and cost efficient, this limita-
tion may be acceptable and reflects general clinical 
practice.
Conclusions
The investigated cross-sector telemetric net-
work using a non-invasive ER is a feasible approach 
to detect arrhythmia in patients with palpitations 
and may have high impact on further treatment, 
notably in those at risk for stroke due to AF.
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